Effect of Ivabradine on the Infarct size and Remodeling in Patients with STEMI

Abstract

Coronary artery disease remains the leading cause of mortality worldwide. Despite advances in primary and secondary prevention, including revascularization, the condition continues to impose a major burden upon public health. Increase in heart rate induced by physical or emotional effort is well known as an important determinant of ischemia. Ivabradine is a new heart rate reducing agent, which has demonstrated anti-anginal and anti-ischemic properties in patients with stable angina. It is hypothesized that addition of ivabradine to standard medical therapy would have a beneficial effect in decreasing the infarct size through the heart rate reduction in acute coronary syndrome specially in patients presented with STEMI. The aim of our study to assess the effect of ivabradine on LV function and remodeling in patients with STEMI after primary PCI (PPCI). Eighty patients who presented with STEMI within the time window of reperfusion (12hrs) were included in our study. The patients were divided into two groups: Group 1: optimal medical treatment (OMT) including beta-blockers +Ivabradine;